Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

High levels of traumatic stress found in caregivers of adult cancer patients

2.

Alecensa (alectinib) Offers Hope for Certain Patients With ALK Positive NSCLC

3.

Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

4.

Losing a reward can affect your motivation and performance.

5.

Study: Rapamycin slows the progression of cancer by reducing aging and concentrating on precancerous cells.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot